Poll

How concerned are you about the cost of prostate cancer treatment for your patients?

Very concerned
Somewhat concerned
Not at all concerned

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Christine Ibilibor, MD, highlights study of racial differences in abiraterone use
Christine Ibilibor, MD, highlights study of racial differences in abiraterone use
Laura Davis, MD, on persistent poverty and early onset prostate cancer
Laura Davis, MD, on persistent poverty and early onset prostate cancer
Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
Ruben Olivares, MD, answers a question during a Zoom video interview
Ruben Olivares, MD, discusses HIFU and remote prostate cancer care
Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Post-RP incontinence: Low procedure rates examined
Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
Data link incontinence severity to post-radical prostatectomy care
Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Expert discusses differentiating prostate cancer from age-related issues
Related Content
Irreversible electroporation with NanoKnife found safe, effective for prostate tissue ablation
July 22nd 2025

Irreversible electroporation with NanoKnife found safe, effective for prostate tissue ablation

Hannah Clarke
The PRESERVE trial met its primary end point by demonstrating a negative in-field biopsy rate of 71% at 12 months.
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
July 18th 2025

Phase 3 TALAPRO-2 data of talazoparib plus enzalutamide published in The Lancet

Hannah Clarke
In both cohorts, the combination of talazoparib plus enzalutamide led to a significant improvement in overall survival vs enzalutamide alone.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
CMS issues reimbursement code for PSMA-PET imaging agent Gozellix
July 15th 2025

CMS issues reimbursement code for PSMA-PET imaging agent Gozellix

Hannah Clarke
The level II code A9616 will be effective starting on October 1, 2025.
Carotuximab plus apalutamide demonstrates safety, tolerability in mCRPC
July 15th 2025

Carotuximab plus apalutamide demonstrates safety, tolerability in mCRPC

Hannah Clarke
The company said it plans to report interim efficacy data from the trial in September 2025.
© 2025 MJH Life Sciences

All rights reserved.